Privo Technologies is proud to serve as both an exhibitor and selected speaker at the RESI conference in Boston... read more

Privo Technologies is honored to receive a Phase 2 award for $2M from the NIDCR SBIR program to further develop its scale-up, chemistry, and manufacturing program. read more

BOSTON, Oct. 24, 2018 /PRNewswire/ -- Privo Technologies was granted the green light from the FDA and several hospitals this summer... read more

Privo Technologies is pleased to announce that the company has won the 2016 National Tibbetts award for outstanding contributions... read more

The Salisbury Award Competition is a set of competitions participated in by investigators at major cancer research institutions and/or scientists... read more

Privo Technologies attends BIO International Convention as an invited guest of the National Institute of Dental and Craniofacial Research... read more

Privo Technologies is honored to receive a Phase 1 award for $220,000 from the NIDCR SBIR program to further develop its scale-up, chemistry, and manufacturing program. read more

Privo Technologies received Orphan Designation for anatomically accessible oral cancers. Receipt of this designation entitles Privo’s current and future... read more

Privo a $2.5M grant to optimize it lead product and prepare for its IND. read more

Privo Technologies has been awarded ~$2 million in funding from the FDA through its Office of Orphan Product Development... read more